Global healthcare logistics company Maken Korea is presenting its precision logistics strategies at the 'BioPlus-Interphex Korea 2026 (BIX 2026)' exhibition, which runs until October 30 at COEX in Seoul. The company aims to assist domestic pharmaceutical and biotech firms in expanding internationally by addressing the challenges posed by geopolitical risks and disruptions in global supply chains.
On October 30, Maken Korea announced that it will showcase its cold chain logistics solutions, including a demonstration of liquid nitrogen (LN2) storage. The company plans to emphasize a proactive risk management system that assesses potential hazards during the transportation of pharmaceuticals. This includes developing emergency response plans that consider transportation routes, local logistics environments, and temperature control conditions to minimize the risk of supply chain disruptions. Maken Korea aims to ensure the continuity of drug quality and supply schedules, even in the face of unexpected variables.
The company also introduced its 'Clinical-to-Commercial' strategy, which connects the logistics of clinical trial drugs to the storage and distribution of commercial pharmaceuticals after approval. Maken Korea focuses on maintaining consistency in quality control and regulatory compliance at each stage, recognizing that clinical trial drugs and commercial products differ in volume and operational methods. The company aims to serve as an integrated logistics partner for domestic firms, supporting them from the early stages of new drug development to their entry into international markets.
Advanced biopharmaceuticals, such as cell and gene therapies (CGT), are also a key area of focus. Due to the personalized nature of these treatments, strict identification and tracking management, as well as temperature maintenance, are essential. In the 'Vein-to-Vein' supply chain, which encompasses everything from patient cell collection to manufacturing, transportation, and administration, it is crucial to have a system for verifying the match between patients and treatments (CoI) and to track management histories at each stage (CoC). Maken Korea stated that it will systematically manage the handling conditions and movement histories of pharmaceuticals to provide patient-centered precision logistics services.
“As global supply chain uncertainties increase, the competitiveness of pharmaceutical logistics lies not only in transportation speed but also in maintaining stable supply amidst unexpected variables,” said Ahn Sun-ok, head of Maken Korea. “We will support domestic companies in responding to supply chain risks and expanding overseas by leveraging our integrated logistics capabilities and global network that connect clinical trials to commercialization.”
Meanwhile, BIX 2026 is a three-day exhibition for the pharmaceutical and biotech industries taking place at COEX in Seoul until October 30, featuring over 300 companies from both domestic and international markets with 600 booths.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.